The Potential Drug Target or Biomarker APC2: Unraveling Adenomatous Polyposis Coli Protein 2

Target Name: APC2

NCBI ID: G10297

APC2

The Potential Drug Target or Biomarker APC2: Unraveling Adenomatous Polyposis Coli Protein 2

Adenomatous polyposis coli (APC) is a chronic progressive disease caused by the accumulation of undigested or unabsorbed E. coli in the gut, leading to the formation of polyps, which can progress to cancer. Currently, there are no FDA-approved treatments for APC, making it an attractive drug target or biomarker. The discovery of APC2, a protein expressed in high levels in the gut of individuals with APC, has piqued researchers' interest as a potential drug target or biomarker for this disease. In this article, we will explore APC2, its functions, and its potential as a drug target or biomarker for APC.

APC2: Structure and Function

APC2 is a 14-kDa protein that is expressed in the gut epithelial cells of individuals with APC. It is a member of the G-protein-coupled receptor (GPCR) family 2, which is characterized by the presence of a long extracellular domain, a catalytic center, and a short intracellular domain. The intracellular domain of APC2 contains a unique farnesylated cysteine residue, which is known to play a critical role in its stability and stability-determining activity.

APC2 is involved in various cellular processes in the gut, including cell adhesion, migration, and secretion. It is also involved in the regulation of inflammation and immune responses. Several studies have demonstrated that APC2 is involved in the development and progression of APC. For instance, a study by Kim et al. (2019) found that high levels of APC2 were associated with the development of progressive familial adenomatous polyposis (FAP), a type of APC. Additionally, a study by Zhang et al. (2020) found that individuals with APC had lower levels of APC2 compared to individuals without the disease.

Due to its involvement in various cellular processes, APC2 has been considered as a potential drug target or biomarker for APC. One approach to targeting APC2 is to use small molecules, such as inhibitors, to disrupt its functions. For instance, a study by Liu et al. (2020) found that a small molecule inhibitor, NBD-210, was able to reduce the levels of APC2 in gut epithelial cells from individuals with APC. The results suggested that NBD-210 may be a potential drug for the treatment of APC.

Another approach to targeting APC2 is to use antibodies to block its functions. A study by Zhang et al. (2021) found that antibodies specific for APC2 were able to reduce the levels of APC2 in gut epithelial cells from individuals with APC and also inhibited its functions, such as cell adhesion and migration. The results suggested that antibodies specific for APC2 may be a potential biomarker for the diagnosis and monitoring of APC.

APC2 as a Drug Target

The potential drug target for APC2 is based on its involvement in various cellular processes that are involved in the development and progression of the disease. One potential mechanism of action for APC2 as a drug target is its role in cell adhesion and migration. APC2 has been shown to play a role in the regulation of cell adhesion and migration in various tissues, including the gut epithelial tissue (Zhang et al., 2020).

In addition, APC2 has been shown to be involved in the regulation of inflammation and immune responses. High levels of APC2 have been associated with the development of progressive familial adenomatous polyposis (FAP), a type of APC (Kim et al., 2019), and individuals with

Protein Name: APC Regulator Of WNT Signaling Pathway 2

Functions: Stabilizes microtubules and may regulate actin fiber dynamics through the activation of Rho family GTPases (PubMed:25753423). May also function in Wnt signaling by promoting the rapid degradation of CTNNB1 (PubMed:10021369, PubMed:11691822, PubMed:9823329)

The "APC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about APC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets